4.5 Article

Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Pharmacology & Pharmacy

Population Pharmacokinetic and Exposure-Response Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn's Disease

Ahmed Abbas Suleiman et al.

Summary: Population pharmacokinetics of risankizumab were characterized using data from phase II and III studies in patients with Crohn's disease. Exposure-response analyses showed that the 600 mg intravenous (i.v.) induction dose achieved a near maximal response for all efficacy end points. The maintenance treatment of 360 mg subcutaneous every-8-weeks (Q8W) regimen showed higher responses for most of the evaluated efficacy end points.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Medication non-adherence in inflammatory bowel diseases is associated with disability

Jonathan Perry et al.

INTESTINAL RESEARCH (2018)

Review Gastroenterology & Hepatology

Medication adherence in inflammatory bowel disease

Webber Chan et al.

INTESTINAL RESEARCH (2017)

Article Gastroenterology & Hepatology

Medication non-adherence is associated with increased medical health care costs

Sunanda Kane et al.

DIGESTIVE DISEASES AND SCIENCES (2008)

Article Psychology, Developmental

Medication adherence and quality of life in pediatric inflammatory bowel disease

Kevin A. Hommel et al.

JOURNAL OF PEDIATRIC PSYCHOLOGY (2008)

Review Medicine, General & Internal

Drug therapy - Adherence to medication

L Osterberg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Article Medicine, General & Internal

Medication Nonadherence and the outcomes of patients with quiescent ulcerative colitis

S Kane et al.

AMERICAN JOURNAL OF MEDICINE (2003)